Table 1 Baseline characteristics of the study cohort.
Characteristics | Cohort (n = 1394) |
|---|---|
Age, yr | 4 (0–11) |
Age categories, n (%) | |
Infancy, 1 mo−1 yr | 504 (36.2) |
Childhood, 2–10 yr | 502 (36.0) |
Adolescent, 11–18 yr | 388 (27.8) |
Sex, male, n (%) | 817 (58.6) |
AKI type, n (%) | |
Community-acquired AKI | 343 (24.6) |
Hospital-acquired AKI | 1051 (75.4) |
AKI stage, n (%) | |
Stage 1 | 844 (60.5) |
Stage 2 | 319 (22.9) |
Stage 3 | 231 (16.6) |
Clinical settings, n (%) | |
Sepsis | 181 (13.0) |
Glomerulonephritis | 57 (4.1) |
Nephrotic syndrome | 156 (11.2) |
CKDa | 15 (1.1) |
Urinary tract obstruction/malformation | 25 (1.8) |
Non-cardiac surgery | 72 (5.2) |
Congenital heart disease/cardiac surgery | 451 (32.4) |
Heart failure | 114 (8.2) |
Inherited metabolic disease | 24 (1.7) |
Cardiac arrest | 12 (0.9) |
Trauma/burn | 27 (1.9) |
Shock | 61 (4.4) |
Respiratory failure | 120 (8.6) |
Diarrhea/dehydration | 56 (4.0) |
Nephrotoxic drugs | 673 (48.3) |
Laboratory data | |
Hemoglobin, g/L | 111 (92–126) |
< 90 | 313 (22.5) |
White blood cells, × 109/L | 9.4 (5.7–14.6) |
< 4 | 227 (16.3) |
> 10 | 649 (46.6) |
Platelets, × 109/L | 229 (138–345) |
< 100 | 239 (17.1) |
Proteinuria, n (%) | 261 (22.7) |
Serum albumin, g/L | 36.8 (30.3–41.0) |
< 30 | 332 (23.9) |
Serum total bilirubin, μmol/L | 9.5 (5.2–18.2) |
> 34.2 | 156 (11.2) |
Serum potassium, mmol/L | 4.4 (3.9–4.9) |
< 3.5 | 144 (10.5) |
> 5.5 | 89 (6.5) |
Serum sodium, mmol/L | 138 (136–140) |
< 135 | 271 (19.9) |
> 145 | 56 (4.1) |
Loop diuretics, n (%) | 736 (52.8) |
Mechanical ventilation, n (%) | 274 (19.7) |
RRT, n (%) | 105 (7.5) |
